Fixed-duration therapy with ibrutinib and obinutuzumab (GA-101) in treatment-naïve patients with CLL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514824-18-00

Enrollment

Registered

2024-08-05

Start date

2021-09-16

Completion date

Unknown

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic lymphocytic leukemia/small lymphocytic lymphoma

Brief summary

Percentage of patients with MRD <10-4 in BM at +30 follow-up days after completion of therapy

Interventions

DRUGOBINUTUZUMAB

DRUGIBRUTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients with MRD <10-4 in BM at +30 follow-up days after completion of therapy	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026